Investment Pitches

Pitch Summary:
One of the top contributors to our Strategy’s performance in the quarter was Lamar Advertising (LAMR), the nation’s leading out-of-home advertising company. LAMR, which operates as a real estate investment trust, had been underperforming for much of the year. It recently provided a solid Q3 report and very favorable outlook causing the stock to rally. When it comes to stock selection, we like to see improving fundamentals confirmed by actions of management through active share buybacks, insider buying, and growing dividends. These are all signs of management’s confidence in the future profits and cash flows of their respective companies. A majority of the companies in our portfolio are active in at least two of these three focus areas. LAMR is one of these companies, as the company has been active on its buyback program and increased its dividend this year. LAMR’s pacings have been strong, which should lead to positive earnings growth in 2026. Even better, 2026 brings with it the mid-term election cycle, which should boost political advertising spending on Lamar’s properties. Still, the stock trades at a reasonable valuation of around 15 times 2026 Enterprise Value/EBITDA.

BSD Analysis:
Lamar’s moat is physical scarcity—billboards in good locations are hard to permit and hard to replace. Digital conversions improve pricing and utilization, creating real operating leverage. But it’s still ad spend: demand softens when local economies wobble. The failure mode is recession-driven pricing pressure plus higher rates squeezing REIT multiples. Regulatory constraints protect the asset base, but they also limit growth to conversions and acquisitions. The bull case is steady cash generation with inflation-linked pricing and digital upside. The bear case is multiple compression from rates and a cyclical ad downturn. Lamar is a toll road with macro sensitivity. It’s defensive-ish, not immune.

Pitch Summary:
A good illustration that true value can be realized with patience is Alexander & Baldwin (ALEX). When we originally initiated a position in this Hawaii-based real estate investment trust in the summer of 2024, we were significantly underweight in our Real Estate exposure, relative to our benchmark. From a risk/reward standpoint, ALEX looked favorable to most other REITs at the time. We liked how ALEX divested a non-core construction business, making this a pure-play REIT with assets strictly in Hawaii. And we were drawn to historically low industrial vacancies in the State as well as the company’s strong absorption rate relative to its peers. Over the past six months, however, Alexander & Baldwin shares sold off materially over concerns of slowing tourism in Hawaii. This is despite the fact that little of ALEX’s properties are on resorts or directly exposed to travel. Actual real estate fundamentals in the Aloha State remain strong with industrial vacancies hovering at just around 2%. The company also enjoyed a robust pipeline of pre-leased developments to drive earnings growth and a strong balance sheet with below-average leverage, at 3.5x net debt to EBITDA. Nevertheless, the stock was down more than 14% through the first two months of the quarter — until Dec. 8, when a group of investors agreed to take the company private at a 40% premium, which was close to our evaluation of fair value. While ALEX wasn’t a huge winner, the takeout boosted the holding’s performance to close out the year and demonstrated that other investors are starting to pay attention to the companies we focus on.

BSD Analysis:
A&B is essentially a Hawaii real estate bet—scarcity is the moat and regulation is the tax. Land and redevelopment in Hawaii can be valuable, but the pathway is slow, political, and unpredictable. Cash flows can look stable, yet value realization depends on entitlements and timing. The failure mode is capital trapped in long-duration projects while rates stay high. Concentration risk is massive: one geography, one regulatory ecosystem. The bull case is steady monetization of scarce assets with patient capital. The bear case is chronic friction that caps returns and keeps the multiple low. A&B is scarcity with bureaucracy attached. Great assets don’t guarantee great equity outcomes.

Pitch Summary:
Another position we increased was Columbus McKinnon (CMCO), which designs, manufactures, and distributes materials, handling products, and systems used in a variety of industrial applications, including lifting, automation, and precision conveyance. Early this year, CMCO reported slower-than-expected Q3 results, citing slowing industry demand driven by U.S. policy uncertainty. By itself, that would have likely triggered a mid-single-digit to high-single-digit selloff based on historic price reactions. However, management also announced a $2.7 billion acquisition of a competitor, Kito Crosby, which sent the stock plummeting more than 40% due to concerns surrounding execution and an increased leverage profile upon closing. At current prices, we believe Columbus has a compelling risk/reward profile as management seeks to reduce leverage and improve the growth and margin profile of the consolidated business. Management is targeting mid-20% EBITDA margins upon integration, up from 15.5% in FY25 pre-acquisition. In our opinion, CMCO can rerate closer to its industrial peers that trade at an average of 12x EV/EBITDA. Meanwhile, our view of the stock’s attractive valuations seems to be validated by aggressive insider buying by management in the aftermath of the Q3 selloff.

BSD Analysis:
Columbus McKinnon sells lifting and motion-control equipment where reliability and installed base matter. The moat is service relationships and niche engineering, but end markets are cyclical. The failure mode is industrial slowdown plus fixed-cost deleverage. M&A can add scale, but integration risk is real in industrial roll-ups. Pricing power exists in specialized applications, not across the board. The bull case is secular automation and safety demand layered onto cycle recovery. The bear case is margin compression when volume drops and customers delay capex. CMCO is cyclical quality, not secular certainty. It wins when industrial activity turns up.

Pitch Summary:
An example of a Health Care holding that struggled in the quarter was Integer Holdings Corporation (ITGR), which specializes in the design, development, and production of medical technologies and components. In late October, Integer’s stock sank more than 30% after the company significantly lowered its outlook for growth and margin expansion in 2026, as several products experienced slower market adoption than was expected. But management expects these headwinds to be short-lived, with a robust portfolio of higher growth and margin products coming to market, which should allow the company to get back on track. The company still expects to outgrow its industry peers by 2% while growing earnings before interest and taxes (EBIT) at twice the rate of sales. Even better, the company announced a $200 million stock repurchase authorization after the selloff, increasing our conviction that the shares are materially undervalued. This confidence drove us to increase our exposure to Integer in the quarter.

BSD Analysis:
Integer is a picks-and-shovels medtech supplier—less glamorous than OEMs, but often stickier than investors assume. The moat is qualification and switching friction: regulated components don’t get swapped lightly. Growth comes from outsourcing trends and content per procedure, not headline innovation. The failure mode is customer concentration and program ramps that disappoint. Margins depend on manufacturing execution and mix—small errors become big in regulated supply chains. The bull case is steady medtech volume growth with operating leverage. The bear case is pricing pressure from OEMs and utilization shortfalls. Integer is a “quiet compounder” if execution stays clean. If execution slips, it trades like a commodity manufacturer.

Pitch Summary:
One holding that ran into difficulties last quarter is Kimberly Clark (KMB), the tissue company behind well-known brands such as Huggies, Cottonelle, and Kleenex. The consumer products giant saw its shares fall more than 14% in November, not because of poor results or sub-par execution. Instead, the stock sank immediately after KMB announced its $48.7 billion acquisition of Kenvue, the consumer health company spun off from Johnson & Johnson which sells Tylenol, Neutrogena, Band-Aid and Listerine. We disagree with management’s capital allocation decision, as it takes KMB into new categories and poses significant integration risk. We find it unfortunate that management made such an aggressive move after executing well against an internally focused playbook that positioned KMB for value creation in the coming years. We fear that the Kenvue deal makes the company “bigger, not necessarily better”. We trimmed the position in response to the Kenvue announcement. However, we balance deal-related question marks against a valuation of 13 times earnings (a historically wide discount to peers), better market share trends and improved margin performance in recent years.

BSD Analysis:
Kimberly-Clark is staples defense: diapers, tissue, and hygiene with steady demand and limited excitement. The moat is shelf space, scale manufacturing, and brand trust, but private label keeps pricing power honest. Inflation periods make the P&L look heroic; later, volumes tell the truth. The failure mode is margin squeeze from pulp/input costs plus consumers trading down. Growth is modest, so capital allocation and cost discipline matter more than “innovation.” The bull case is stable cash flow and buybacks in a volatile macro. The bear case is a value trap if structurally low growth meets multiple compression. KMB is a bond substitute with operational risk. You buy it for stability—just don’t expect surprises.

Pitch Summary:
In the quarter, we initiated a new position in MarketAxess Holdings (MKTX), a Quality Value company that owns and operates the largest e-trading platform in the U.S. for corporate bonds. Bonds are largely traded over the counter, unlike equities or listed derivatives, which are traded on exchanges. Operating a trading platform is all about scale, where volume determines profitability. Rising customer activity can be a virtuous circle that begets more trading as depth of liquidity improves for all platform participants. Improved liquidity, in turn, drives down trading costs, which then attracts even more volume. Scaled trading platforms can be extremely profitable. MKTX’s operating margin, for example, exceeds 40% while gross margin can exceed 75%. Though MarketAxess pioneered electronic bond trading, prior management rested on their laurels as peers launched new trading protocols that gained market share. MKTX’s bread and butter is providing leading market depth in single-bond trading. But the industry has witnessed the rapid adoption of “portfolio trading” (PT), where asset owners can bundle a portfolio of bonds and receive better pricing versus trading on a bond-by-bond basis. Tight corporate bond credit spreads as of late have exacerbated the shift to PT. CEO Chris Concannon has led a multi-year initiative to invest in a competing PT product among other value-added tools being launched by MKTX. Management has chosen not to wait for a better market environment to advance their efforts. As a result of this push, the company’s operating margin declined to around 41% last year, down from more than 45% in 2022. We have been encouraged by recent trading data that suggest MKTX is gaining share in key areas of the U.S. credit market, with share recovery happening even faster than we expected. Looking forward, moderating investment spend should result in better operating leverage. We also believe the company’s international and emerging markets businesses, where electronic trading penetration is lower than in the U.S., have significant growth opportunity and scale advantages. When we purchased the stock in the fourth quarter, MarketAxess was trading at 12.6 times consensus EV/EBITDA estimates for 2026. Since then, the multiple has expanded to 13.7 times. This is still favorable to the company’s domestic exchange peers, who are trading at a median multiple of 16.6 times, despite MKTX’s superior profit margins and balance sheet.

BSD Analysis:
MarketAxess is a network-effects business in credit trading—liquidity begets liquidity, until it doesn’t. The moat is market structure: electronic trading penetration keeps rising, and MarketAxess sits in the flow. But revenue is volume-sensitive, and credit markets can go quiet fast. Competition is relentless from dealers, rival platforms, and internalization attempts. The failure mode is disintermediation—if the biggest participants route around you, the network weakens. The bull case is continued electronification plus stronger protocol adoption across credit. The bear case is share loss in key products and a lower “platform premium” multiple. MarketAxess is a toll road—great when traffic is forced through it. If traffic finds side streets, it de-rates hard.

Pitch Summary:
J.B. Hunt, which falls into the Deep Value bucket, is a diversified transportation company focusing on intermodal shipping. Customers hire Hunt to move freight using different methods of transportation to reduce cost. The company owns the largest fleet of 53-foot shipping containers, which allow for three ocean-freight shipping units to be consolidated into two Hunt containers that can then be moved by rail and company-owned trucks. Hunt’s “mode agnostic” approach sets it apart from the competition, as does its size. JBHT’s intermodal business is roughly twice as big as the next largest competitor, resulting in a scale and cost advantage that has produced high returns on capital and better prices for customers. In recent years, the freight market has been put through the wringer, as supply chains during and after the pandemic experienced a tremendous amount of volatility. In Q3, however, Hunt beat analysts’ forecasts, owing to recent actions to reduce costs. Management’s focus on improving areas that they can control seems to be working, as operating margins for JBHT’s intermodal segment expanded by 100 basis points year over year, despite fewer loads shipped in the quarter. While managing through a freight recession, cash flow generation remains strong, the company’s balance sheet is in fantastic shape with a leverage ratio of less than 1x, and management has been aggressively repurchasing company stock below our view of intrinsic value. In 2025, the company bought back more than 5% of the shares outstanding. JBHT currently trades at 11.8 times consensus next 12-month EV/EBITDA, which represents a 25% discount to the Industrial sector. Earnings expectations over the next 12 months have fallen 30% from prior cycle peak levels, though, Hunt typically trades at a premium when earnings bottom.

BSD Analysis:
J.B. Hunt’s moat is scale in intermodal and dedicated, where network density and service reliability matter more than spot pricing. It’s a high-quality operator in a low-quality industry—execution is the edge. Intermodal benefits structurally when rail service is good and trucking capacity tight, but both conditions cycle. The failure mode is a freight downturn plus weak rail performance, compressing volumes and margins simultaneously. Dedicated is stickier, but contract resets still reflect macro reality. The bull case is normalization of freight with operating leverage and share gains. The bear case is prolonged weak demand and pressure on rates. JBHT is a quality cyclical—don’t pay compounder multiples for cycle exposure.

Pitch Summary:
Georgia Capital, a conglomerate of several high-quality businesses in the Republic of Georgia, had a truly outstanding year. The net asset value (NAV) of their portfolio companies rapidly increased and shares were aggressively repurchased, increasing NAV per share by 41% (in GEL) in just the first 9 months of 2025. Additionally, the Georgian Lari (GEL) gained against the USD by 4.36% in 2025. Overall, the economy of Georgia has been extremely strong this year with rising standards of living and high GDP growth. A little over half of CGEO’s portfolio is comprised of private businesses that are valued in their NAV calculation based on net income or EBITDA multiples. As their private portfolio companies had rapid earnings growth in 2025, this also increased the NAV. Their only publicly-traded holding is the Lion Finance Group PLC (formerly Bank of Georgia Group PLC), which doubled in share price in 2025 on strong growth and earnings. The management company pursued aggressive deleveraging and executed early redemption of $100M USD of its $150M USD local bonds. Their healthcare operations purchased a local firm, Gormed LLC, which had 3 clinics in central Georgia. Their insurance business exited loss-making contracts, improved underwriting, increased premiums, and achieved better combined ratios and returns on equity in the high 30s. Despite the dramatic share price increase in 2025, Georgia Capital still trades at a discount to its most recent NAV calculation (share price is £31.15 vs £40.93 NAV) and remains cheap relative to the operating cash flow of their underlying businesses.

BSD Analysis:
Georgia Capital is a holding-company bet on Georgian domestic growth with a persistent “discount to NAV” problem. The moat is access and local expertise—hard for outsiders to replicate—but that doesn’t guarantee shareholder-friendly outcomes. Returns depend on capital allocation and exits, not quarterly earnings smoothness. The failure mode is governance plus liquidity: small markets trap capital and amplify political shocks. FX and country risk are not side notes; they’re the thesis. The bull case is NAV compounding with buybacks that actually shrink the discount. The bear case is permanent discount plus episodic political risk that crushes multiples. Georgia Capital is about patience and governance—without those, it’s just volatility.

Pitch Summary:
Enova continued growing organically in 2025. Year-over-year originations grew by 22% in Q3 2025. They have added new retail and business borrowers and their underwriting algorithms are continuously updated. Machine learning models are retrained frequently (in some cases daily), and these models drive their underwriting decisions (85% of which are completely automated). Their models materially improve repayment predictability versus bureau scores alone. And most importantly, the information in their customer databases continues to accumulate, which is the fuel for their data-driven underwriting process. They also continued with their share buybacks, reducing share count more than 5% over 12 months from 26.27M in Q3 2024 to 24.88M shares in Q3 2025. These buybacks have been ongoing for several years. At the beginning of Q3 2021, they were at 36.87M shares. The biggest jump in stock price came in December after Enova announced the acquisition of Grasshopper Bank. This acquisition has the potential to be particularly transformative due to the synergies between the two companies. Enova is paying Grasshopper $369M in cash and stock for the acquisition (Enova ended the year with a market cap of $4.4B). Despite the increased share count, the transaction is expected to be accretive to EPS. The guidance from Enova is that once the synergies are fully realized beyond the first year, they expect EPS increase attributable to this acquisition to be greater than 25%. Founded in 2019, Grasshopper is full-service digital bank with more than $1.4 billion in total assets as of September 30, 2025. Through its direct and Banking-as-a-Service (BaaS) product offerings, Grasshopper holds approximately $3 billion in total deposits as of September 30, 2025. These deposits are low-cost and sticky compared to Enova’s current funding, significantly reducing the financing costs for Enova’s lending and therefore boosting their net interest margin. Enova is acquiring Grasshopper Bank primarily to pair Enova’s online consumer and SMB lending business with a full-service digital bank and national bank charter, creating a diversified and more vertically integrated financial services platform. This merger will open up many new lines of business for Enova and will allow them to offer new banking and lending products in many of the states where they operate. Enova is a rapidly growing fintech that has returned capital through buybacks and has a long runway of future growth ahead of it. It is amazing that even after the recent share price increase, the stock can still be purchased for 9x the consensus estimate of their FY2027 earnings.

BSD Analysis:
Enova is a non-prime lender whose “moat” is really underwriting, data, and the willingness to live where banks won’t. The business can look like a cash machine in benign credit regimes, then remind you it’s a leverage-to-loss-cycle model when delinquencies roll. The edge is speed: pricing risk, cutting originations, and shifting product mix faster than slower institutions. The failure mode is obvious—funding costs spike, credit losses rise, and the spread evaporates. Regulation is a permanent shadow; non-prime lending is politically easy to target. The bull case is disciplined underwriting plus stable funding that keeps ROE high. The bear case is a recession with tightened liquidity where “data advantage” becomes irrelevant. Enova is a risk-transfer business—great when managed ruthlessly, lethal when not.

Pitch Summary:
We also sold our position in Netflix after the company agreed to acquire Warner Brothers (minus Discovery Global) for $83 billion. Even though the Warner Brothers content would assuredly strengthen Netflix’s content library and competitive differentiation, it would come with significant regulatory risk and balance sheet leverage above our comfort level.

BSD Analysis:
Netflix has completed the hard transition from a growth-at-any-cost streamer to a global entertainment platform built to generate real cash flow. Subscriber additions matter less now than monetization per user, and Netflix has more levers than ever to pull. Advertising is scaling into a meaningful profit stream without undermining the core subscription model. Content spend is finally disciplined, turning scale into margin rather than just audience. Global reach remains a massive advantage, letting Netflix amortize hits across markets competitors can’t access efficiently. Churn stays low because Netflix still owns the broadest must-watch library. Investors worry about saturation, but pricing power and ad monetization extend the runway. This is no longer a speculative media bet — it’s a cash-generating distribution monopoly. As execution stays tight, Netflix’s earnings profile should continue to surprise on the upside.

Pitch Summary:
At the same time, we exited our position in Workday as the company's revenue growth continues to decelerate. The core human capital management business is fairly mature and now facing cyclical headwinds while the newer financials suite is growing slower than expected.

BSD Analysis:
Workday runs core HR and finance systems for large enterprises. Switching costs are enormous. Growth has slowed but remains durable. Margin expansion is the next lever. AI improves workflows without disrupting the model. Investors worry about competition. But incumbency matters. Workday compounds through cycles. This is enterprise software with staying power.

Pitch Summary:
We initiated a 2.25% position in Intuitive Surgical who maintain a de facto monopoly in soft tissue robotic surgery globally. They have become the standard of care in many surgical modalities while there are many more open and laparoscopic surgeries that can be converted to robotic over time. The barriers to entering their market are large based on decades of proven efficacy and safety, as well as the fact most surgeons are trained on the company's Da Vinci robots either in medical school or on the job, and they continue to innovate and distance themselves from potential entrants. The company recently fully launched its next generation platform that should lead to accelerating procedure growth and revenue growth for years. Current results show this acceleration, and we see clear business momentum and a reasonable valuation considering this is an accelerating monopoly.

BSD Analysis:
Intuitive Surgical owns robotic surgery mindshare. The installed base creates recurring revenue through instruments and services. Adoption continues across procedures and geographies. Hospitals hesitate to switch platforms. Innovation cadence sustains pricing power. Capital spending cycles affect timing, not demand. Investors fixate on valuation. But dominance deserves a premium. This is medtech infrastructure.

Pitch Summary:
The primary drag for the quarter was Oracle, accounting for almost all of the Portfolio’s relative underperformance in Q4, completely reversing its performance from the prior quarter and giving back all of the gains experienced in Q3. In line with waning market enthusiasm in the AI trade, Oracle’s massive increase in RPO’s (remaining performance obligations, which are essentially contracted future revenues) have been met with increased skepticism given the large percentage which is tied to OpenAI and the associated question marks over OpenAI’s ability to finance itself and therefore make good on those commitments. It would appear that investors are focused on the increasing threats of execution risk and financing risk for both Oracle and OpenAI, as opposed to the excitement of prior quarters around the magnitude of the numbers. While we recognize and acknowledge these risks, it is our belief that the range of potential outcomes are skewed positively in Oracle’s favor and that the stock reaction is another example of the ‘shoot first, ask questions later’ mindset of the market today and so retain conviction in our exposure.

BSD Analysis:
Oracle has quietly repositioned as a serious cloud infrastructure provider. OCI wins specialized workloads where performance matters. Long-term contracts provide revenue visibility. Legacy database cash funds growth. Investors still think “old tech.” AI workloads benefit Oracle’s architecture. Margins improve with scale. This is legacy reinvented, not fading. Execution keeps surprising skeptics.

Pitch Summary:
Eli Lilly was the top performing relative contributor in Q4. Lilly’s stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. However, the stock rallied over 40% in Q4 driven by strong financial results, strengthening market leadership in key business segments, along with reaching an agreement with the White House that while lowering GLP-1 drug prices will greatly increase the addressable market in the U.S. and should allow for a long runway of future growth ahead.

BSD Analysis:
Eli Lilly is executing one of the strongest drug cycles in decades. Obesity and diabetes therapies redefine standard of care. Demand exceeds supply, shifting risk to manufacturing scale. Pricing power reflects outcome-based value. The pipeline beyond GLP-1s remains deep. Political noise persists but hasn’t dented momentum. Investors debate peak sales too early. Lilly keeps expanding indications. This is pharma dominance backed by science.

Pitch Summary:
However, select holdings in consumer staples and health care did face pressure. Following a period of strong performance, shares of e.l.f. Beauty, a cosmetics company focused on affordable, digitally native products, declined as sales growth was hurt by management’s decision to stop shipments to retailers that were slow to pass through tariff-related price increases. That said, we are encouraged that consumption trends for the brand remain healthy and management is already seeing shipment growth recover in the current quarter.

BSD Analysis:
e.l.f. is a rare beauty disruptor that’s translated virality into sustained retail velocity. The moat is brand momentum plus a value proposition that keeps working in both trade-down and trend-up environments. The concentration risk is that beauty is brutally trend-driven—what’s hot becomes “last season” fast. Growth is also channel-dependent: retailer relationships and shelf space are oxygen. Margins can hold if product innovation stays tight; they collapse if promotions creep in. The bull case is continued share gains and category expansion with disciplined marketing. The bear case is momentum reversal and inventory-driven discounting. Valuation assumes the brand stays culturally relevant. e.l.f. wins when it keeps the product flywheel spinning.

Pitch Summary:
Fourth-quarter outperformance was driven by a combination of balanced portfolio construction and strong stock selection. Early in the quarter, momentum tied to AI and technology supported results, while the portfolio’s exposure to steadier compounders and defensive growth names helped protect performance as volatility increased. Within IT, Shopify, an e-commerce platform that enables merchants to operate and scale digital storefronts, benefited from continued adoption by larger enterprises and improving monetization across its ecosystem.

BSD Analysis:
Shopify is the merchant OS for brands that don’t want to rent their future from marketplaces. The moat is ecosystem gravity—apps, payments, partners—and switching costs that only become obvious once you try to leave. Growth now depends on monetization depth and moving upmarket, not just adding stores. Merchant health is cyclical, so GMV sensitivity is unavoidable. Shopify’s strategic discipline improved after stepping back from capital-heavy logistics dreams. Competition is permanent, but most rivals can’t match ecosystem breadth. The bull case is durable take-rate expansion and services attach. The bear case is commoditization at the low end and slowing growth optics at scale. Shopify is a platform with real value—still priced on expectations.

Pitch Summary:
SurgePays is positioned as a high-risk, high-reward investment, with significant potential for growth through its diversified revenue streams. The company has transitioned from the Affordable Connectivity Program to the Lifeline program, rapidly scaling its subscriber base to over 125K by Q3 2025. SurgePays is leveraging its existing infrastructure to expand into new business areas, including prepaid wireless services, MVNE partnerships, and fintech solutions through convenience stores. The company aims to reach a cash flow breakeven point by the end of December 2025 with a target of 200K Lifeline subscribers. Despite recent stock price volatility, the company's innovative approach and strategic partnerships suggest potential for significant upside.

BSD Analysis:
SurgePays has demonstrated impressive growth in its subscriber base and revenue streams, capitalizing on its ability to pivot from the ACP to the Lifeline program. The company's strategy of integrating its services into convenience stores via the Phone-in-a-Box product and POS software creates a recurring revenue model that could drive long-term profitability. The ClearLine digital marketing platform and LogicsIQ engine further enhance SurgePays' ability to monetize consumer data and expand its market reach. While the company faces challenges such as negative gross margins and cash flow constraints, management's confidence in achieving FY26 revenue guidance of $225M underscores the potential for substantial returns. Investors should be mindful of the risks associated with financing needs and market volatility but recognize the transformative potential of SurgePays' business model.